Skip to main content
Fig. 8 | Molecular Medicine

Fig. 8

From: Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma

Fig. 8

Vanoxerine dihydrochloride and 5-FU treatments reduced tumor growth in vivo in nude mice xenografted with Huh7 cells. BALB/C nude mice xenografted with Huh7 cells were treated with vanoxerine dihydrochloride (40 mg/kg), 5-Fu (10 mg/kg), vanoxerine dihydrochloride (40 mg/kg) plus 5-Fu (10 mg/kg), and PBS for 21 days by daily i.p. injections. a Tumor volumes. b Tumor weight as compared to control at day 21 after treatment. c Body weight. dg The representative pictures of immunohistochemistry staining of the xenografted tumor tissues for d Rb, e CDK2, f CDK4, and g CDK6 expressions. **p < 0.01, significantly different from the control PBS treatment group

Back to article page
\